Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT

Courtney D. Fitzhugh, Matthew M. Hsieh, Tiffani Taylor, Wynona Coles, Katherine Roskom, Delon Wilson, Elizabeth Wright, Neal Jeffries, Christopher Gamper, Jonathan Powell, Leo Luznik, John F. Tisdale

Research output: Contribution to journalArticle

Abstract

Peripheral blood stem cell transplantation (PBSCT) offers a curative option for sickle cell disease (SCD). Although HLA-matched sibling transplantation is promising, the vast majority of patients lack such a donor. We sought to develop a novel nonmyeloablative HLA-haploidentical PBSCT approach that could safely be used for patients with severe organ damage. Based on findings in our preclinical model, we developed a phase 1/2 trial using alemtuzumab, 400 cGy total body irradiation, and escalating doses of posttransplant cyclophosphamide (PT-Cy): 0 mg/kg in cohort 1, 50 mg/kg in cohort 2, and 100 mg/kg in cohort 3. A total of 21 patients with SCD and 2 with b-thalassemia received a transplant. The mean hematopoietic cell transplant–specific comorbidity index of 6 reflected patients with cirrhosis, heart failure, and end-stage renal disease. The engraftment rate improved from 1 (33%) of 3 in cohort 1 to 5 (63%) of 8 in cohort 2 and 10 (83%) of 12 in cohort 3. Percentage of donor myeloid and CD3 chimerism also improved with subsequent cohorts. There was no transplant-related mortality, and overall survival was 87%. At present, 0% in cohort 1, 25% in cohort 2, and 50% in cohort 3 remain free of their disease. There was no grade 2 to 4 acute or extensive chronic graft-versus-host disease (GVHD). Therefore, PT-Cy improves engraftment and successfully prevents severe GVHD after nonmyeloablative conditioning in patients with SCD who are at high risk for early mortality. Additional strategies are necessary to decrease the graft rejection rate and achieve a widely available cure for all patients with SCD.

Original languageEnglish (US)
Pages (from-to)652-661
Number of pages10
JournalBlood Advances
Volume1
Issue number11
DOIs
StatePublished - Apr 25 2017

Fingerprint

Peripheral Blood Stem Cell Transplantation
Sickle Cell Anemia
Cyclophosphamide
Graft vs Host Disease
Tissue Donors
Transplants
Chimerism
Thalassemia
Mortality
Whole-Body Irradiation
Graft Rejection
Chronic Kidney Failure
Comorbidity
Siblings
Fibrosis
Heart Failure
Transplantation
Survival

ASJC Scopus subject areas

  • Hematology

Cite this

Fitzhugh, C. D., Hsieh, M. M., Taylor, T., Coles, W., Roskom, K., Wilson, D., ... Tisdale, J. F. (2017). Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT. Blood Advances, 1(11), 652-661. https://doi.org/10.1182/bloodadvances.2016002972

Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT. / Fitzhugh, Courtney D.; Hsieh, Matthew M.; Taylor, Tiffani; Coles, Wynona; Roskom, Katherine; Wilson, Delon; Wright, Elizabeth; Jeffries, Neal; Gamper, Christopher; Powell, Jonathan; Luznik, Leo; Tisdale, John F.

In: Blood Advances, Vol. 1, No. 11, 25.04.2017, p. 652-661.

Research output: Contribution to journalArticle

Fitzhugh, CD, Hsieh, MM, Taylor, T, Coles, W, Roskom, K, Wilson, D, Wright, E, Jeffries, N, Gamper, C, Powell, J, Luznik, L & Tisdale, JF 2017, 'Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT', Blood Advances, vol. 1, no. 11, pp. 652-661. https://doi.org/10.1182/bloodadvances.2016002972
Fitzhugh, Courtney D. ; Hsieh, Matthew M. ; Taylor, Tiffani ; Coles, Wynona ; Roskom, Katherine ; Wilson, Delon ; Wright, Elizabeth ; Jeffries, Neal ; Gamper, Christopher ; Powell, Jonathan ; Luznik, Leo ; Tisdale, John F. / Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT. In: Blood Advances. 2017 ; Vol. 1, No. 11. pp. 652-661.
@article{adb658cb93ed451c814b325dc6955a69,
title = "Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT",
abstract = "Peripheral blood stem cell transplantation (PBSCT) offers a curative option for sickle cell disease (SCD). Although HLA-matched sibling transplantation is promising, the vast majority of patients lack such a donor. We sought to develop a novel nonmyeloablative HLA-haploidentical PBSCT approach that could safely be used for patients with severe organ damage. Based on findings in our preclinical model, we developed a phase 1/2 trial using alemtuzumab, 400 cGy total body irradiation, and escalating doses of posttransplant cyclophosphamide (PT-Cy): 0 mg/kg in cohort 1, 50 mg/kg in cohort 2, and 100 mg/kg in cohort 3. A total of 21 patients with SCD and 2 with b-thalassemia received a transplant. The mean hematopoietic cell transplant–specific comorbidity index of 6 reflected patients with cirrhosis, heart failure, and end-stage renal disease. The engraftment rate improved from 1 (33{\%}) of 3 in cohort 1 to 5 (63{\%}) of 8 in cohort 2 and 10 (83{\%}) of 12 in cohort 3. Percentage of donor myeloid and CD3 chimerism also improved with subsequent cohorts. There was no transplant-related mortality, and overall survival was 87{\%}. At present, 0{\%} in cohort 1, 25{\%} in cohort 2, and 50{\%} in cohort 3 remain free of their disease. There was no grade 2 to 4 acute or extensive chronic graft-versus-host disease (GVHD). Therefore, PT-Cy improves engraftment and successfully prevents severe GVHD after nonmyeloablative conditioning in patients with SCD who are at high risk for early mortality. Additional strategies are necessary to decrease the graft rejection rate and achieve a widely available cure for all patients with SCD.",
author = "Fitzhugh, {Courtney D.} and Hsieh, {Matthew M.} and Tiffani Taylor and Wynona Coles and Katherine Roskom and Delon Wilson and Elizabeth Wright and Neal Jeffries and Christopher Gamper and Jonathan Powell and Leo Luznik and Tisdale, {John F.}",
year = "2017",
month = "4",
day = "25",
doi = "10.1182/bloodadvances.2016002972",
language = "English (US)",
volume = "1",
pages = "652--661",
journal = "Blood advances",
issn = "2473-9529",
publisher = "American Society of Hematology",
number = "11",

}

TY - JOUR

T1 - Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT

AU - Fitzhugh, Courtney D.

AU - Hsieh, Matthew M.

AU - Taylor, Tiffani

AU - Coles, Wynona

AU - Roskom, Katherine

AU - Wilson, Delon

AU - Wright, Elizabeth

AU - Jeffries, Neal

AU - Gamper, Christopher

AU - Powell, Jonathan

AU - Luznik, Leo

AU - Tisdale, John F.

PY - 2017/4/25

Y1 - 2017/4/25

N2 - Peripheral blood stem cell transplantation (PBSCT) offers a curative option for sickle cell disease (SCD). Although HLA-matched sibling transplantation is promising, the vast majority of patients lack such a donor. We sought to develop a novel nonmyeloablative HLA-haploidentical PBSCT approach that could safely be used for patients with severe organ damage. Based on findings in our preclinical model, we developed a phase 1/2 trial using alemtuzumab, 400 cGy total body irradiation, and escalating doses of posttransplant cyclophosphamide (PT-Cy): 0 mg/kg in cohort 1, 50 mg/kg in cohort 2, and 100 mg/kg in cohort 3. A total of 21 patients with SCD and 2 with b-thalassemia received a transplant. The mean hematopoietic cell transplant–specific comorbidity index of 6 reflected patients with cirrhosis, heart failure, and end-stage renal disease. The engraftment rate improved from 1 (33%) of 3 in cohort 1 to 5 (63%) of 8 in cohort 2 and 10 (83%) of 12 in cohort 3. Percentage of donor myeloid and CD3 chimerism also improved with subsequent cohorts. There was no transplant-related mortality, and overall survival was 87%. At present, 0% in cohort 1, 25% in cohort 2, and 50% in cohort 3 remain free of their disease. There was no grade 2 to 4 acute or extensive chronic graft-versus-host disease (GVHD). Therefore, PT-Cy improves engraftment and successfully prevents severe GVHD after nonmyeloablative conditioning in patients with SCD who are at high risk for early mortality. Additional strategies are necessary to decrease the graft rejection rate and achieve a widely available cure for all patients with SCD.

AB - Peripheral blood stem cell transplantation (PBSCT) offers a curative option for sickle cell disease (SCD). Although HLA-matched sibling transplantation is promising, the vast majority of patients lack such a donor. We sought to develop a novel nonmyeloablative HLA-haploidentical PBSCT approach that could safely be used for patients with severe organ damage. Based on findings in our preclinical model, we developed a phase 1/2 trial using alemtuzumab, 400 cGy total body irradiation, and escalating doses of posttransplant cyclophosphamide (PT-Cy): 0 mg/kg in cohort 1, 50 mg/kg in cohort 2, and 100 mg/kg in cohort 3. A total of 21 patients with SCD and 2 with b-thalassemia received a transplant. The mean hematopoietic cell transplant–specific comorbidity index of 6 reflected patients with cirrhosis, heart failure, and end-stage renal disease. The engraftment rate improved from 1 (33%) of 3 in cohort 1 to 5 (63%) of 8 in cohort 2 and 10 (83%) of 12 in cohort 3. Percentage of donor myeloid and CD3 chimerism also improved with subsequent cohorts. There was no transplant-related mortality, and overall survival was 87%. At present, 0% in cohort 1, 25% in cohort 2, and 50% in cohort 3 remain free of their disease. There was no grade 2 to 4 acute or extensive chronic graft-versus-host disease (GVHD). Therefore, PT-Cy improves engraftment and successfully prevents severe GVHD after nonmyeloablative conditioning in patients with SCD who are at high risk for early mortality. Additional strategies are necessary to decrease the graft rejection rate and achieve a widely available cure for all patients with SCD.

UR - http://www.scopus.com/inward/record.url?scp=85032494569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032494569&partnerID=8YFLogxK

U2 - 10.1182/bloodadvances.2016002972

DO - 10.1182/bloodadvances.2016002972

M3 - Article

AN - SCOPUS:85032494569

VL - 1

SP - 652

EP - 661

JO - Blood advances

JF - Blood advances

SN - 2473-9529

IS - 11

ER -